Our top pick for
Nevro Corp is a medical devices business based in the US. Nevro shares (NVRO) are listed on the NYSE and all prices are listed in US Dollars. Nevro employs 843 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$119.17|
|52-week range||$99.54 - $188.14|
|50-day moving average||$120.51|
|200-day moving average||$141.25|
|Wall St. target price||$139.62|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.97|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||2.19%|
|1 month (2021-09-21)||-3.72%|
|3 months (2021-07-21)||-22.75%|
|6 months (2021-04-21)||-26.01%|
|1 year (2020-10-20)||-20.85%|
|2 years (2019-10-18)||40.20%|
|3 years (2018-10-19)||136.92%|
|5 years (2016-10-20)||20.23%|
|Revenue TTM||$409.1 million|
|Gross profit TTM||$249.9 million|
|Return on assets TTM||-3.95%|
|Return on equity TTM||-18.63%|
|Market capitalisation||$4.1 billion|
TTM: trailing 12 months
There are currently 2.3 million Nevro shares held short by investors – that's known as Nevro's "short interest". This figure is 3.8% down from 2.4 million last month.
There are a few different ways that this level of interest in shorting Nevro shares can be evaluated.
Nevro's "short interest ratio" (SIR) is the quantity of Nevro shares currently shorted divided by the average quantity of Nevro shares traded daily (recently around 392260.27164686). Nevro's SIR currently stands at 5.89. In other words for every 100,000 Nevro shares traded daily on the market, roughly 5890 shares are currently held short.
However Nevro's short interest can also be evaluated against the total number of Nevro shares, or, against the total number of tradable Nevro shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nevro's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Nevro shares in existence, roughly 70 shares are currently held short) or 0.0675% of the tradable shares (for every 100,000 tradable Nevro shares, roughly 68 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nevro.
Find out more about how you can short Nevro stock.
We're not expecting Nevro to pay a dividend over the next 12 months.
Nevro's shares were split on a 1:24 basis on 5 November 2014. So if you had owned 24 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nevro shares – just the quantity. However, indirectly, the new 2300% higher share price could have impacted the market appetite for Nevro shares which in turn could have impacted Nevro's share price.
Over the last 12 months, Nevro's shares have ranged in value from as little as $99.54 up to $188.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Nevro's is 1.0571. This would suggest that Nevro's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Nevro Corp. , a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.